# Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis

Study · id `cardio:ct-nct01785849` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01785849](<https://clinicaltrials.gov/study/NCT01785849>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01785849

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 508 participants.

## Technical summary

Registry record NCT01785849. Randomized; triple masking; primary purpose treatment. Start 2013-03-12 (actual); primary completion 2014-05-22 (actual). Results posted on 2017-03-27.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 508 participants (enrolled count; ClinicalTrials.gov record NCT01785849, source copy `cardio:ctgov-nct01785849-2019-08-26`, retrieved 2026-10-26)
- Started: 2013-03-12 (actual) (ClinicalTrials.gov record NCT01785849, source copy `cardio:ctgov-nct01785849-2019-08-26`, retrieved 2026-10-26)
- Primary completion: 2014-05-22 (actual) (ClinicalTrials.gov record NCT01785849, source copy `cardio:ctgov-nct01785849-2019-08-26`, retrieved 2026-10-26)
- Completion: 2014-06-12 (actual) (ClinicalTrials.gov record NCT01785849, source copy `cardio:ctgov-nct01785849-2019-08-26`, retrieved 2026-10-26)
- Results first posted: 2017-03-27 (ClinicalTrials.gov record NCT01785849, source copy `cardio:ctgov-nct01785849-2019-08-26`, retrieved 2026-10-26)
- Countries: United States; Australia; Austria; Belgium; Canada; Czechia; France; Germany; Hungary; Israel; Italy; Poland; Russia; Spain; United Kingdom (ClinicalTrials.gov record NCT01785849, source copy `cardio:ctgov-nct01785849-2019-08-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01785849-2019-08-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis
- Condition: Hyperparathyroidism, Secondary
- Intervention (Drug): Etelcalcetide
- Intervention (Drug): Placebo
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: 278dc2a921ddbd01cf99c3f29cbb4ba072ed70543dad81d939a3e53769b5e270
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
